Ascentage Pharma to Present Olverembatinib and Lisaftoclax Clinical Data at ASH Annual Meeting
China-based Ascentage Pharma (HKG: 6855) has announced that it will present the results of multiple...
Drug
CStone Pharmaceuticals Presents CS5001 Clinical Data at the ASH Annual Meeting
China-based CStone Pharmaceuticals (HKG: 2616) has announced the presentation of the latest clinical data on...
Roche to Showcase 40+ Abstracts on Blood Disorders at ASH Annual Meeting
Swiss pharmaceutical giant Roche (SWX: ROG) has announced plans to present over 40 abstracts across...
China Medical System’s Opzelura Approved in Hong Kong for Non-segmental Vitiligo Treatment
China Medical System Holdings (CMS; HKG: 0867) has announced that the market filing for its...
Legend Biotech to Showcase CARTITUDE-4 Trial Data on Carvykti at ASH Annual Meeting
China-based Legend Biotech Corporation (NASDAQ: LEGN) is set to present new data on minimal residual...
Asieris Pharmaceuticals Receives NMPA Approval for Hexvix (APL-1706) in Bladder Cancer Diagnosis
China-based urogenital cancer specialist Asieris Pharmaceuticals (SHA: 688176) has announced that the National Medical Products...
Frontier Biotechnologies Inc. Gets NMPA Approval for Phase II Study of Albuvirtide as HIV Therapy
Nanjing-based Frontier Biotechnologies Inc. (SHA: 688221) has received approval from the National Medical Products Administration...
Windtree Therapeutics Secures Hong Kong Patent for Istaroxime Heart Failure Treatment
US biotechnology company Windtree Therapeutics, Inc. (NASDAQ: WINT) has announced the receipt of a patent...
BMS’s Opdivo Secures NMPA Approval for Urothelial Carcinoma Treatment
Bristol Myers Squibb (BMS; NYSE: BMY) has announced that it has received another indication approval...
HuidaGene Receives FDA Clinical Clearance for HG202 in Neovascular AMD Treatment
China-based HuidaGene (Shanghai) Biotechnology Co., Ltd has announced receiving clinical clearance from the US Food...
Isap Biotech Secures FDA IND Approval for iSAP-0909 for Bladder Cancer Imaging
Beijing-based biotech firm Isap Biotech has announced that it has received Investigational New Drug (IND)...
China Grand Pharmaceutical Completes Phase III Clinical Study for Post-Cataract Surgery Treatment
China Grand Pharmaceutical and Healthcare Holdings Ltd (HKG: 0512; CGP) has announced the successful completion...
Innorna Co., Ltd Receives FDA Rare Pediatric Disease Designation for mRNA Drug IN015
Shenzhen-based Innorna Co., Ltd has announced that it has received Rare Pediatric Disease Designation (RPDD)...
Teva Pharmaceutical Reports Positive Phase III Results for TEV-‘749 in Schizophrenia Trial
Israel-based Teva Pharmaceutical Industries Ltd (NYSE: TEVA) has released new positive data on social functioning...
Novo Nordisk’s Semaglutide Meets Primary Endpoints in ESSENCE Phase III Study for MASH
Denmark-based pharmaceutical company Novo Nordisk (NYSE: NVO; CPH: Novo-B) has announced that part 1 of...
Jiuzhitang Co., Ltd Announces Clinical Clearance for Volagidemab in Type 1 Diabetes
China-based traditional Chinese medicine (TCM) giant Jiuzhitang Co., Ltd (SHE: 000989) has announced that volagidemab...
Shenzhen Chipscreen Biosciences Receives NMPA Approval for Chiauranib Clinical Study
China-based biopharmaceutical company Shenzhen Chipscreen Biosciences Co., Ltd (SHA: 688321) has received approval from the...
Novartis’ Trispecific Antibody PIT565 Secures NMPA Approval for Clinical Trial
Swiss pharmaceutical giant Novartis (NYSE: NVS) has received acceptance for its clinical trial application for...
Shenzhen Chipscreen Biosciences’ Tivozanib Secures NMPA Approval for ES-SCLC Phase III Trial
Shenzhen Chipscreen Biosciences Co., Ltd. (SHA: 688321) has announced that the National Medical Products Administration...
Humanwell Healthcare Receives NMPA Approval for Compound Sodium Lactate Ringer’s Injection
Humanwell Healthcare (Group) Co., Ltd (SHA: 600079) has received approval from the National Medical Products...